Our Focus
Climate Action
Recognizing that social and environmental impacts caused by climate change are urgent issues, we collect and analyze the required data in accordance with the way of the Task Force on Climate-related Financial Disclosures (TCFD).
In December 2023, we submitted a letter of commitment to the SBT Initiative (SBTi), which certifies science-based targets (SBT), the targets for reducing greenhouse gas emissions under the Paris Agreement, and we are currently advancing considerations to establish and have certified targets for the reduction of greenhouse gas emissions within two years.
Governance
Governance
At the company, the Sustainability Committee formulates and monitors strategies on climate change and reports the details to the Board of Directors and the Management Committee.
Strategy
Strategy
As a company that plays a part in the drug supply chain, our company group regards the identification and reduction of GHG emissions as an important issue and is advancing initiatives towards the realization of the decarbonized society that the Paris Agreement aims for. In addition to Scopes 1 and 2, we measure and monitor Scope 3 emissions based on the GHG Protocol to grasp the complete picture of the GHG emissions in our company’s supply chain. In December 2023, we submitted a letter of commitment to the SBT Initiative (SBTi), which certifies science-based targets (SBT), the targets for reducing greenhouse gas emissions under the Paris Agreement, and we are currently advancing considerations to establish and have certified targets for the reduction of greenhouse gas emissions within two years.
The Sustainability Committee confirms the impact of the opportunities and risks of climate change on the Group's business model, which is centered on providing clinical trial-related services such as contract monitoring services, with reference to the scenario analysis of the pharmaceutical companies that are our company group’s customers. It has evaluated that the impact on business of transition risks such as increased costs due to carbon pricing and stricter regulations will not be large at the Linical Group, which does not have manufacturing facilities and does not require the procurement of raw materials. On the other hand, we recognize the following as physical risks and opportunities, and are responding to each in turn.
|
Physical risk |
Opportunity |
|
Temporary suspension of operations at business sites due to the interruption of energy or communication networks, etc., due to a large-scale natural disaster |
Increased development of new drugs by customers (pharmaceutical companies) in response to epidemics of tropical diseases and emerging infectious diseases |
|
Decline in the level of operations due to an emerging infectious disease epidemic |
We have formulated a Business Continuity Plan (BCP) to address the physical risks above and are reviewing it and implementing training continuously. In addition, we will expand our bases, including Southeast Asia and the Southern Hemisphere, to contribute to the development of drugs for the diseases above.
Risk Management
Risk Management
With regard to climate change risks, the Sustainability Committee analyzes the company group’s GHG emission risks, makes recommendations to the Risk Management Committee, and monitors them.
Metrics and Targets
Metrics and Targets
In December 2023, we submitted a letter of commitment to the SBT Initiative (SBTi), which certifies science-based targets (SBT), the targets for reducing greenhouse gas emissions under the Paris Agreement, and we are currently advancing considerations to establish and have certified targets for the reduction of greenhouse gas emissions within two years.